mutLBSgeneDB |
Gene summary for PTPN3 |
Gene summary |
Basic gene Info. | Gene symbol | PTPN3 |
Gene name | protein tyrosine phosphatase, non-receptor type 3 | |
Synonyms | PTP-H1|PTPH1 | |
Cytomap | UCSC genome browser: 9q31 | |
Type of gene | protein-coding | |
RefGenes | NM_001145368.1, NM_001145369.1,NM_001145370.1,NM_001145371.1,NM_001145372.1, NM_002829.3,NR_026918.1, | |
Description | cytoskeletal-associated protein tyrosine phosphataseprotein-tyrosine phosphatase H1tyrosine-protein phosphatase non-receptor type 3 | |
Modification date | 20141207 | |
dbXrefs | MIM : 176877 | |
HGNC : HGNC | ||
Ensembl : ENSG00000070159 | ||
HPRD : 06767 | ||
Vega : OTTHUMG00000020475 | ||
Protein | UniProt: P26045 go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_PTPN3 | |
BioGPS: 5774 | ||
Pathway | NCI Pathway Interaction Database: PTPN3 | |
KEGG: PTPN3 | ||
REACTOME: PTPN3 | ||
Pathway Commons: PTPN3 | ||
Context | iHOP: PTPN3 | |
ligand binding site mutation search in PubMed: PTPN3 | ||
UCL Cancer Institute: PTPN3 | ||
Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. |
Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
GO ID | GO Term | PubMed ID | GO:0006470 | protein dephosphorylation | 10364224 | GO:0035335 | peptidyl-tyrosine dephosphorylation | 19167335 | GO:0045930 | negative regulation of mitotic cell cycle | 10364224 | GO:0098902 | regulation of membrane depolarization during action potential | 16930557 | GO:2000649 | regulation of sodium ion transmembrane transporter activity | 16930557 |
Top |
Ligand binding site mutations for PTPN3 |
Cancer type specific mutLBS sorted by frequency |
LBS | AAchange of nsSNV | Cancer type | # samples | H812 | H812R | COAD | 1 | H812 | H812N | COAD | 1 | H812 | V814L | LUAD | 1 | R751 | R751Q | LUSC | 1 | H812 | H812L | OV | 1 | D811 | D811E | OV | 1 | R751 | R749Q | SKCM | 1 |
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
Top |
Protein structure related information for PTPN3 |
Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
: nsSNV at non-LBS: nsSNV at LBS |
nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
LBS | AAchange of nsSNV | Relative stability change | R751 | R749Q | -1.2380085 | R751 | R751Q | -1.1991519 | H812 | V814L | -0.97127467 | H812 | H812N | -0.82061073 | D811 | D811E | -0.66336574 | H812 | H812R | -0.42677227 | H812 | H812L | -0.045749782 |
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
Structure image for PTPN3 from PDB |
Top |
Differential gene expression and gene-gene network for PTPN3 |
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
Top |
Top |
Phenotype information for PTPN3 |
Gene level disease information (DisGeNet) |
Disease ID | Disease name | # PubMed | Association type |
Mutation level pathogenic information (ClinVar annotation) |
Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
Top |
Pharmacological information for PTPN3 |
Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
Drug information targeting mutLBSgene (Approved drugs only) |
Drug status | DrugBank ID | Name | Type | Drug structure |
Gene-centered ligand-gene interaction network |
Ligands binding to mutated ligand binding site of PTPN3 go to BioLip |
Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | VO4 | VANADATE(3-) | 4ri4 | A | D811 | VO4 | VANADATE(3-) | 4ri4 | B | D811 | III | Peptide ligand (PHE,SER,ALA,TYR,PRO,SER) | 4rh5 | A | H812 | III | Peptide ligand (PHE,SER,ALA,TYR,PRO,SER,GLU) | 4rhg | A | H812 | III | Peptide ligand (PHE,SER,ALA,TYR,VAL,SER) | 4s0g | A | H812 | III | Peptide ligand (MET,THR,GLY,TYR,VAL,VAL,THR,ARG) | 4qum | A | R751 H812 |
Top |
Conservation information for LBS of PTPN3 |
Multiple alignments for P26045 in multiple species |
LBS | AA sequence | # species | Species |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |